Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Retained Earnings: 2016-2024

Historic Retained Earnings for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to -$164.0 million.

  • Collegium Pharmaceutical's Retained Earnings rose 33.11% to -$118.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$118.1 million, marking a year-over-year increase of 33.11%. This contributed to the annual value of -$164.0 million for FY2024, which is 29.67% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Retained Earnings stood at -$164.0 million for FY2024, which was up 29.67% from -$233.2 million recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Retained Earnings ranged from a high of $5.3 million in FY2020 and a low of -$281.3 million during FY2022.
  • Its 3-year average for Retained Earnings is -$226.2 million, with a median of -$233.2 million in 2023.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Retained Earnings soared by 101.47% in 2020, and later crashed by 4,947.62% in 2021.
  • Yearly analysis of 5 years shows Collegium Pharmaceutical's Retained Earnings stood at $5.3 million in 2020, then plummeted by 4,947.62% to -$256.3 million in 2021, then dropped by 9.75% to -$281.3 million in 2022, then climbed by 17.12% to -$233.2 million in 2023, then rose by 29.67% to -$164.0 million in 2024.